Original Article

Expression of miR-127, miR-154, and miR-183 in Medullary Thy-roid Carcinoma Tumors


Background: Medullary thyroid cancer (MTC) accounts for 5%–10% of all thyroid cancers, but causes 13% of all thyroid cancer related deaths. MicroRNAs (miRs) have key functions in the development and progression of MTC. Altered expression of some miRs has been reported in many human cancers, including Thyroid cancer. Therefore, we aimed to analyze the expression of miR-154, miR-183 and miR-127 in MTC tumor tissues.

Methods: In this case-control study, 15 MTC Formalin-fixed, paraffin-embedded (FFPE) tissue samples and 15 adjacent normal thyroid FFPE tissues, as a control group, were collected from Taleghani, and Loghman Hakim Hospitals, Tehran, Iran since 2005 till 2015. After RNA extraction and cDNA synthesis, the expression of miR-127, miR-154 and miR-183 was measured by quantitative Real-Time Polymerase Chain Reaction (qRT-PCR).

Results: Our data showed a significant increase in the expression of miR-127 in MTC samples in comparison with the control group (P<0.05). Although miR-154 and miR-183 expression levels had increase expression in MTC tumors, this change was not statistically significant.

Conclusion: The miR-127 could be considered as a prognostic, diagnostic and therapeutic marker for the management of MTC, and it is proposed for further investigation to fully establish the role of this miRNA in MTC.

1. Rajabi S, Dehghan MH, Dastmalchi R, et al (2019). The roles and role-players in thyroid cancer angiogenesis. Endocr J, 66 (4): 277-293.
2. Hedayati M, Zarif Yeganeh M, Sheikholeslami S, Afsari F (2016). Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer. Crit Rev Clin Lab Sci, 53 (4): 217-27.
3. Hedayati M, Nabipour I, Rezaei-Ghaleh N, Azizi F (2006). Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases. Med j Malaysia, 6 (5): 564-9.
4. Randle RW, Balentine CJ, Leverson GE, et al (2017). Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery, 161 (1): 137-146.
5. Mathiesen JS, Kroustrup JP, Vestergaard P, et al (2018). Incidence and prevalence of sporadic and hereditary MTC in Denmark 1960-2014: a nationwide study. Endocr Connect, 7 (6): 829-839.
6. Opsahl EM, Brauckhoff M, Schlichting E, et al (2016). A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma. Thyroid, 26 (9): 1225-38.
7. Mian C, Pennelli G, Barollo S, et al (2011). Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinoly, 164 (6): 971-6.
8. Yeganeh MZ, Sheikholeslami S, Dehbashi Behbahani G, et al (2015). Skewed mutational spectrum of RET proto-oncogene Exon10 in Iranian patients with medullary thyroid carcinoma. Tumour Biol, 36 (7): 5225-5231.
9. Yeganeh MZ, Sheikholeslami S, Hedayati M (2015). RET proto oncogene mutation detection and medullary thyroid carcinoma prevention. Asian Pac J Cancer Prev, 16 (6): 2107-17.
10. Lotfi J, Taghikhani M, Yeganeh MZ, et al (2014). Plasma levels of osteocalcin and retinol binding protein-4 in patients with medullary thyroid carcinoma. TUMJ, 72 (1): 22-26.
11. Rajabi S, Hedayati M (2017). Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases. Mol Diagn Ther, 21 (6): 607-620.
12. Sharma S, Kelly TK, Jones PA (2010). Epigenetics in cancer (2010). Carcinogenesis, 31 (1): 27-36.
13. Sheervalilou R, Shirvaliloo S, Fekri Aval S, et al (2017). A new insight on reciprocal relationship between microRNA expression and epigenetic modifications in human lung cancer. Tumor Biol, 39 (5): 1010428317695032.
14. Fardi M, Solali S, Farshdousti Hagh M (2018). Epigenetic mechanisms as a new approach in cancer treatment: An updated review. Genes Dis, 5 (4): 304-311.
15. Yong Sun Lee, Anindya Dutta (2009). MicroRNAs in cancer. Annu Rev Pathol, 4:199-227.
16. Marini F, Luzi E, Brandi ML (2011). MicroRNA Role in Thyroid Cancer Development. J Thyroid Res, 2011:407123.
17. Leonardi GC, Candido S, Carbone M, et al (2012). microRNAs and thyroid cancer: Biological and clinical significance. Int J Mol Med, 30 (5): 991-9.
18. Ehyaei S, Hedayati M, Zarif-Yeganeh M, et al (2017). Plasma Calcitonin Levels and miRNA323 Expression in Medullary Thyroid Carcinoma Patients with or without RET Mutation. Asian Pac J Cancer Prev, 18 (8): 2179-84.
19. Nikiforova MN, Tseng GC, Steward D, et al (2008). MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab, 93 (5): 1600-8.
20. Mian C, Pennelli G, Fassan M, et al (2012). MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Thyroid, 22(9):890-6.
21. Abraham D, Jackson N, Gundara JS, et al (2011). MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin Cancer Res, 17(14):4772-81.
22. Becker N, Lockwood CM (2013). Pre-analytical variables in miRNA analysis. Clin Biochem, 46 (10-11): 861-8.
23. Wang S, Li H, Wang J, Wang D, Yao A, Li Q (2014). Prognostic and Biological Significance of MicroRNA-127 Expression in Human Breast Cancer. Dis Markers, 2014: 401986.
24. Chen J, Wang M, Guo M, Xie Y, Cong YS (2013). miR-127 regulates cell proliferation and senescence by targeting BCL6. PloS One, 8(11):e80266.
25. Zhang XL, Pan SH, Yan JJ, Xu G (2018). The prognostic value of microRNA-183 in human cancers: A meta-analysis. Medicine (Baltimore), 97(26): e11213.
26. Lin X, Yang Z, Zhang P, Liu Y, Shao G (2016). miR-154 inhibits migration and invasion of human non-small cell lung cancer by targeting ZEB2. Oncol Lett, 12(1):301-306.
IssueVol 50 No 2 (2021) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v50i2.5358
Medullary thyroid carcinoma Gene expression miR-127 miR-154 miR-183

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
RAHMANI SAMANI M, ZARIF-YEGANEH M, MEHRABI A, EMAMI RAZAVI AN, SHEIKHOLESLAMI S, HEDAYATI M. Expression of miR-127, miR-154, and miR-183 in Medullary Thy-roid Carcinoma Tumors. Iran J Public Health. 50(2):391-396.